One of the buildings of the headquarters of Gilead Sciences, Inc. in Foster City, CA, on April 30, 2020. Its drug, Remdesivir, may be near regulatory authorization in the U.S. as a COVID-19 treatment following early data readouts for a pair of clinical trial. (KEYSTONE/LAIF/Frederic Neema)
Our website uses cookies. By using and navigating through the website and its offers, you accept these cookies. Detailed information about the use of cookies and how to delete them can be found in our data privacy statement.
